Finally, from April 2021, the Japanese Health Authorities has approved Adlumiz (anamorelin), an orally active, high-affinity, selective ghrelin receptor agonist, for the treatment of anorexia, cachexia or unintended weight loss in adult patients with a non-small cell lung cancer (NSCLC). This evidence concerns the gene GHSR and non-small cell lung carcinoma.